FDA Approves Tecentriq to Treat Urothelial Carcinoma

Share this content:
FDA Approves Tecentriq to Treat Urothelial Carcinoma
FDA Approves Tecentriq to Treat Urothelial Carcinoma

THURSDAY, May 19, 2016 (HealthDay News) -- The U.S. Food and Drug Administration has approved atezolizumab (Tecentriq), a PD-1/PD-L1 inhibitor, for treatment of patients with locally-advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

The FDA's approval of Tecentriq is based on a clinical trial involving 310 patients with locally-advanced or metastatic urothelial carcinoma. Nearly 15 percent of patients had at least partial shrinkage of their tumors, which lasted from about two months to nearly 14 months at the time the data was analyzed. Tumor response occurred in 26 percent of patients who were positive for PD-L1 expression, compared with 9.5 percent of those who were negative for PD-L1 expression.

During the clinical trial, common side effects associated with Tecentriq were fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation. The drug also has the potential to cause infection and serious immune system side effects involving healthy organs such as the lungs, colon, and endocrine system, the FDA said.

The FDA also approved a companion test to detect PD-L1 protein expression levels in patients, to help doctors identify those most likely to benefit from Tecentriq.

Tecentriq is made by San Francisco-based Genentech.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

Study Finds 31 Percent Use No Opioids After Surgery

Study Finds 31 Percent Use No Opioids After ...

At discharge, 92.2 percent of patients received an opioid prescription; nearly 63 percent unused

PAs May Have Lower Diagnostic Accuracy for Melanoma

PAs May Have Lower Diagnostic Accuracy for Melanoma

PAs diagnose fewer melanomas in situ, perform more skin biopsies per case of skin cancer diagnosed

AAN: Neuromodulation Therapy Gives Relief From Hand Tremor

AAN: Neuromodulation Therapy Gives Relief From Hand Tremor

Non-invasive neuromodulation therapy using a custom stimulation pattern safe for essential tremor

is free, fast, and customized just for you!

Already a member?

Sign In Now »